A phase II trial of docetaxel and carboplatin as first-line chemotherapy for metastatic breast cancer: NCCTG study N9932

Perez, Edith A., Suman, Vera J., Fitch, Tom R., Mailliard, James A., Ingle, James N., Cole, John T., Veeder, Michael H., Flynn, Patrick J., Walsh, Daniel J. and Addo, Ferdinand K. (2005) A phase II trial of docetaxel and carboplatin as first-line chemotherapy for metastatic breast cancer: NCCTG study N9932. Oncology, 69 2: 117-121. doi:10.1159/000087813


Author Perez, Edith A.
Suman, Vera J.
Fitch, Tom R.
Mailliard, James A.
Ingle, James N.
Cole, John T.
Veeder, Michael H.
Flynn, Patrick J.
Walsh, Daniel J.
Addo, Ferdinand K.
Title A phase II trial of docetaxel and carboplatin as first-line chemotherapy for metastatic breast cancer: NCCTG study N9932
Journal name Oncology   Check publisher's open access policy
ISSN 0030-2414
1423-0232
Publication date 2005-09
Sub-type Article (original research)
DOI 10.1159/000087813
Volume 69
Issue 2
Start page 117
End page 121
Total pages 5
Place of publication Basel, Switzerland
Publisher S. Karger AG
Language eng
Abstract Objective: A phase II multi-institutional clinical trial conducted to evaluate the efficacy and tolerability of docetaxel and carboplatin as first-line therapy for women with metastatic breast cancer. Methods: Patients had histologically confirmed metastatic breast cancer with at least one measurable lesion. Prior adjuvant chemotherapy was permitted, provided that at least 12 months had elapsed between any prior taxane and platinum therapy. Patients received docetaxel 75 mg/m2 with carboplatin AUC 6 mg/ml·min every 21 days until disease progression or prohibitive toxicity. Results: All 53 patients enrolled were evaluable for response and toxicity. Median number of cycles delivered was 6. Overall response rate was 60%, with 3 complete responses (6%) and 29 partial responses (54%). Median time to disease progression was 9.6 months. Median survival time was 20.4 months. Myelosuppression was the predominant toxicity, with grade 3 or 4 neutropenia occurring in 94% of patients and 15% of patients experiencing febrile neutropenia. The overall incidence (grades 1-3) of neurosensory toxicity was 57% and neuromotor toxicity was 25%, respectively, with grade 3 toxicity occurring in 4% of patients each. Conclusions: The combination of docetaxel and carboplatin is highly active in metastatic breast cancer. Prophylactic growth factor support is recommended in any further evaluation of this combination in the treatment of patients with breast cancer.
Keyword breast cancer
clinical trial
docetaxel
carboplatin
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 11 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 11 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 15 Jun 2011, 13:53:15 EST by System User on behalf of School of Medicine